-$0.07 EPS Expected for Opko Health Inc. (OPK) This Quarter

Equities analysts predict that Opko Health Inc. (NASDAQ:OPK) will post earnings of ($0.07) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Opko Health’s earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at ($0.03). Opko Health reported earnings of ($0.08) per share during the same quarter last year, which indicates a positive year over year growth rate of 12.5%. The firm is scheduled to issue its next earnings report on Tuesday, May 14th.

According to Zacks, analysts expect that Opko Health will report full year earnings of ($0.20) per share for the current year, with EPS estimates ranging from ($0.33) to ($0.06). For the next year, analysts anticipate that the company will post earnings of ($0.06) per share, with EPS estimates ranging from ($0.21) to $0.10. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Opko Health.

Opko Health (NASDAQ:OPK) last issued its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. Opko Health had a negative net margin of 15.46% and a negative return on equity of 7.69%. The company had revenue of $221.90 million during the quarter, compared to the consensus estimate of $242.05 million.

A number of research analysts recently issued reports on OPK shares. Barrington Research reiterated a “buy” rating and issued a $5.00 price target on shares of Opko Health in a research note on Thursday, February 28th. Zacks Investment Research downgraded shares of Opko Health from a “buy” rating to a “hold” rating in a research note on Monday, February 4th. Finally, ValuEngine upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Opko Health has an average rating of “Buy” and an average target price of $9.67.

In related news, CEO Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock in a transaction dated Wednesday, April 17th. The stock was acquired at an average price of $2.42 per share, for a total transaction of $121,000.00. Following the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $7,426,861.42. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Vice Chairman Jane Ph D. Hsiao acquired 10,000 shares of Opko Health stock in a transaction dated Thursday, January 31st. The shares were bought at an average price of $7.96 per share, with a total value of $79,600.00. Following the transaction, the insider now directly owns 24,455,147 shares in the company, valued at approximately $194,662,970.12. The disclosure for this purchase can be found here. Insiders purchased 798,000 shares of company stock valued at $2,032,580 in the last quarter. 42.74% of the stock is owned by insiders.

Several large investors have recently modified their holdings of the company. Rhumbline Advisers raised its position in Opko Health by 40.8% in the 4th quarter. Rhumbline Advisers now owns 475,850 shares of the biotechnology company’s stock valued at $1,432,000 after purchasing an additional 137,968 shares during the last quarter. Vanguard Group Inc raised its position in Opko Health by 2.1% in the 3rd quarter. Vanguard Group Inc now owns 29,660,750 shares of the biotechnology company’s stock valued at $102,626,000 after purchasing an additional 614,442 shares during the last quarter. Paloma Partners Management Co purchased a new stake in Opko Health in the 4th quarter valued at $319,000. Strs Ohio raised its position in Opko Health by 27.0% in the 4th quarter. Strs Ohio now owns 112,500 shares of the biotechnology company’s stock valued at $338,000 after purchasing an additional 23,900 shares during the last quarter. Finally, FMR LLC purchased a new stake in Opko Health in the 3rd quarter valued at $2,362,000. Institutional investors and hedge funds own 23.10% of the company’s stock.

Opko Health stock traded down $0.01 during trading on Tuesday, reaching $2.40. The stock had a trading volume of 6,731,012 shares, compared to its average volume of 3,690,665. Opko Health has a 52-week low of $2.34 and a 52-week high of $6.40. The company has a quick ratio of 0.96, a current ratio of 1.10 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.48 billion, a P/E ratio of -9.60 and a beta of 1.88.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

See Also: Are Wall Street analysts’ stock ratings worth following?

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.